{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:22:15Z","timestamp":1775758935771,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"crossref","award":["201810CRU"],"award-info":[{"award-number":["201810CRU"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>While there is robust evidence for strategies to reduce harms of illicit drug use, less attention has been paid to alcohol harm reduction for people experiencing severe alcohol use disorder (AUD), homelessness, and street-based illicit drinking. Managed Alcohol Programs (MAPs) provide safer and regulated sources of alcohol and other supports within a harm reduction framework. To reduce the impacts of heavy long-term alcohol use among MAP participants, cannabis substitution has been identified as a potential therapeutic tool.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To determine the feasibility of cannabis substitution, we conducted a pre-implementation mixed-methods study utilizing structured surveys and open-ended interviews. Data were collected from MAP organizational leaders (<jats:italic>n<\/jats:italic>\u2009=\u20097), program participants (<jats:italic>n<\/jats:italic>\u2009=\u200919), staff and managers (<jats:italic>n<\/jats:italic>\u2009=\u200917) across 6 MAPs in Canada. We used the Consolidated Framework for Implementation Research (CFIR) to inform and organize our analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five themes describing feasibility of CSP implementation in MAPs were identified. The first theme describes the characteristics of potential CSP participants. Among MAP participants, 63% (<jats:italic>n<\/jats:italic>\u2009=\u200912) were already substituting cannabis for alcohol, most often on a weekly basis (<jats:italic>n<\/jats:italic>\u2009=\u20098, 42.1%), for alcohol cravings (<jats:italic>n<\/jats:italic>\u2009=\u200915, 78.9%,) and withdrawal (<jats:italic>n<\/jats:italic>\u2009=\u200910, 52.6%). Most MAP participants expressed willingness to participate in a CSP (<jats:italic>n<\/jats:italic>\u2009=\u200916, 84.2%). The second theme describes the characteristics of a feasible and preferred CSP model according to participants and staff. Participants preferred staff administration of dry, smoked cannabis, followed by edibles and capsules with replacement of some doses of alcohol through a partial substitution model. Themes three and four highlight organizational and contextual factors related to feasibility of implementing CSPs. MAP participants requested peer, social, and counselling supports. Staff requested education resources and enhanced clinical staffing. Critically, program staff and leaders identified that sustainable funding and inexpensive, legal, and reliable sourcing of cannabis are needed to support CSP implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Cannabis substitution was considered feasible by all three groups and in some MAPs residents are already using cannabis. Partial substitution of cannabis for doses of alcohol was preferred. All three groups identified a need for additional supports for implementation including peer support, staff education, and counselling. Sourcing and funding cannabis were identified as primary challenges to successful CSP implementation in MAPs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-021-00512-5","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:04:21Z","timestamp":1624435461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["\u201cIf I knew I could get that every hour instead of alcohol, I would take the cannabis\u201d: need and feasibility of cannabis substitution implementation in Canadian managed alcohol programs"],"prefix":"10.1186","volume":"18","author":[{"given":"Bernie","family":"Pauly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9509-1109","authenticated-orcid":false,"given":"Meaghan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifton","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Wettlaufer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"East Side Illicit Drinkers Group for Education (EIDGE)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Urbanoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Stockwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"512_CR1","unstructured":"World Health Organization. Global status report on alcohol and health 2018. Available from https:\/\/www.who.int\/substance_abuse\/publications\/globa._alc5hol_report\/gsr_2018\/en\/."},{"key":"512_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/009145090903600307","volume":"36","author":"T Stockwell","year":"2009","unstructured":"Stockwell T, et al. The British Columbia alcohol and other drug monitoring system: overview and early progress. Contemp Drug Problems. 2009;36:459\u201384.","journal-title":"Contemp Drug Problems."},{"key":"512_CR3","unstructured":"Canadian Substance Use Costs and Harms Scientific Working Group. Canadian substance use costs and harms (2015\u20132017). 2020. https:\/\/www.ccsa.ca\/canadian-substance-use-costs-and-harms-2015-2017-report."},{"issue":"5","key":"512_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.drugpo.2004.08.002","volume":"15","author":"F Measham","year":"2004","unstructured":"Measham F. Play space: historical and socio-cultural reflections on drugs, licensed leisure locations, commercialisation and control. Int J Drug Policy. 2004;15(5):337\u201345.","journal-title":"Int J Drug Policy"},{"issue":"59","key":"512_CR5","first-page":"85","volume":"2018","author":"A Crabtree","year":"2017","unstructured":"Crabtree A, Latham N, Morgan R, Pauly B, Bungay V, Buxton JA. Perceived harms and harm reduction strategies among people who drink non-beverage alcohol: community-based qualitative research in Vancouver. Can Int J Drug Policy. 2017;2018(59):85\u201393.","journal-title":"Can Int J Drug Policy"},{"issue":"1","key":"512_CR6","first-page":"83","volume":"38","author":"SE Collins","year":"2016","unstructured":"Collins SE. Associations between socioeconomic factors and alcohol outcomes. Alcohol Res Health. 2016;38(1):83\u201394.","journal-title":"Alcohol Res Health"},{"issue":"9929","key":"512_CR7","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(13)62417-4","volume":"383","author":"J Holmes","year":"2014","unstructured":"Holmes J, Meng Y, Meier PS, Brennan A, Angus C, Campbell-Burton A, et al. Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study. The Lancet. 2014;383(9929):1655\u201364.","journal-title":"The Lancet"},{"issue":"11","key":"512_CR8","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/add.13902","volume":"112","author":"J Zhao","year":"2017","unstructured":"Zhao J, Stockwell T. The impacts of minimum alcohol pricing on alcohol attributable morbidity in regions of British Colombia, Canada with low, medium and high mean family income. Addiction. 2017;112(11):1942\u201351.","journal-title":"Addiction"},{"issue":"2","key":"512_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/09595230500102434","volume":"24","author":"R Room","year":"2005","unstructured":"Room R. Stigma, social inequality and alcohol and drug use. Drug Alcohol Rev. 2005;24(2):143\u201355.","journal-title":"Drug Alcohol Rev"},{"issue":"9953","key":"512_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S0140-6736(14)61132-6","volume":"384","author":"S Fazel","year":"2014","unstructured":"Fazel S, Geddes JR, Kushel M. The health of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations. The Lancet. 2014;384(9953):1529\u201340.","journal-title":"The Lancet"},{"key":"512_CR11","doi-asserted-by":"crossref","unstructured":"Collins SE, Clifasefi SL, Dana EA, Andrasik MP, Stahl N, Kirouac M, et al. Where harm reduction meets housing first: exploring alcohol's role in a project-based housing first setting. Int J Drug Policy. 2012.","DOI":"10.1016\/j.drugpo.2011.07.010"},{"issue":"1","key":"512_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/10826084.2017.1322406","volume":"53","author":"SE Collins","year":"2018","unstructured":"Collins SE, Taylor E, Jones C, Haelsig L, Grazioli VS, Mackelprang JL, et al. Content analysis of advantages and disadvantages of drinking among individuals with the lived experience of homelessness and alcohol use dsorders. Subst Use Misuse. 2018;53(1):16\u201325.","journal-title":"Subst Use Misuse"},{"key":"512_CR13","unstructured":"Alexander BK. The roots of addiction in free market society. Vancouver, BC: Canadian Centre for Policy Alternatives; 2000."},{"issue":"6","key":"512_CR14","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/16066350008998987","volume":"8","author":"BK Alexander","year":"2000","unstructured":"Alexander BK. The globalization of addiction. Addict Res. 2000;8(6):501\u201326.","journal-title":"Addict Res"},{"issue":"1","key":"512_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12954-019-0332-4","volume":"16","author":"B Pauly","year":"2019","unstructured":"Pauly B, Brown M, Evans J, Gray E, Schiff R, Ivsins A, et al. \u2018There is a place\u2019: Implementation and impacts of managed alcohol programs for people experiencing severe alcohol dependence and homelessness. Harm Reduct J. 2019;16(1):70.","journal-title":"Harm Reduct J"},{"issue":"1","key":"512_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12954-016-0126-x","volume":"13","author":"A Crabtree","year":"2016","unstructured":"Crabtree A, Latham N, Bird L, Buxton J. Results of a participatory needs assessment demonstrate an opportunity to involve people who use alcohol in drug user activism and harm reduction. Harm Reduct J. 2016;13(1):37.","journal-title":"Harm Reduct J"},{"key":"512_CR17","unstructured":"Bennett D, Larkin DJ. Project inclusion: confronting anti-homeless and substance user stigma in British Columbia, Vancouver; 2019. https:\/\/www.pivotlegal.org\/project_inclusin_full."},{"key":"512_CR18","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1111\/dar.12681","volume":"37","author":"B Pauly","year":"2018","unstructured":"Pauly B, Vallance K, Wettlaufer A, Chow C, Brown R, Evans J, et al. Community managed alcohol programs in Canada: overview of key dimensions and implementation. Drug Alcohol Rev. 2018;37:S132\u20139.","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"512_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/dar.13178","volume":"40","author":"H Carver","year":"2021","unstructured":"Carver H, Parkes T, Browne T, Matheson C, Pauly B. Investigating the need for alcohol harm reduction and managed alcohol programs for people experiencing homelessness and alcohol use disorders in Scotland. Drug Alcohol Rev. 2021;40(2):220\u201330.","journal-title":"Drug Alcohol Rev"},{"issue":"S1","key":"512_CR20","doi-asserted-by":"publisher","first-page":"S184","DOI":"10.1111\/dar.12702","volume":"37","author":"N Ezard","year":"2018","unstructured":"Ezard N, Cecilio ME, Clifford B, Baldry E, Burns L, Day CA, et al. A managed alcohol program in Sydney, Australia: acceptability, cost-savings and non-beverage alcohol use. Drug Alcohol Rev. 2018;37(S1):S184\u201394.","journal-title":"Drug Alcohol Rev"},{"key":"512_CR21","first-page":"1","volume":"2017","author":"T Stockwell","year":"2016","unstructured":"Stockwell T, Pauly B, Chow C, Erickson RA, Krysowaty B, Roemer A, et al. Does managing the consumption of people with severe alcohol dependence reduce harm? A comparison of participants in six Canadian managed alcohol programs with locally recruited controls. Drug Alcohol Rev. 2016;2017:1\u20138.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"512_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12954-016-0102-5","volume":"13","author":"B Pauly","year":"2016","unstructured":"Pauly B, Gray E, Perkin K, Chow C, Vallance K, Krysowaty B, et al. Finding safety: a pilot study of managed alcohol program participants\u2019 perceptions of housing and quality of life. Harm Reduct J. 2016;13(1):15.","journal-title":"Harm Reduct J"},{"issue":"2","key":"512_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/09687637.2020.1764500","volume":"28","author":"B Pauly","year":"2020","unstructured":"Pauly B, King V, Smith A, Tranquilli-Doherty S, Vallance K, Wishart M, et al. Breaking the cycle of survival drinking. Drugs Educ Prev Policy. 2020;28(2):172\u201380.","journal-title":"Drugs Educ Prev Policy."},{"key":"512_CR24","doi-asserted-by":"crossref","unstructured":"Stockwell T, Zhao J, Pauly B, Chow C, Vallance K, Wettlaufer A, et al. Trajectories of alcohol use and related harms for managed alcohol program participants over 12\u00a0months compared with local controls: a quasi-experimental study. Alcohol Alcoholism. 2021; agaa134.","DOI":"10.1093\/alcalc\/agaa134"},{"issue":"1","key":"512_CR25","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hep.23258","volume":"51","author":"RS O'Shea","year":"2010","unstructured":"O\u2019Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver Diseases and the Practice Parameters Committee of the American College of Gastroenterology Alcoholic Liver disease. Hepatology. 2010;51(1):307\u201328.","journal-title":"Hepatology"},{"issue":"9566","key":"512_CR26","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","volume":"369","author":"DJ Nutt","year":"2007","unstructured":"Nutt DJ, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. The Lancet. 2007;369(9566):1047\u201353.","journal-title":"The Lancet"},{"issue":"9752","key":"512_CR27","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","volume":"376","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. The Lancet. 2010;376(9752):1558\u201365.","journal-title":"The Lancet"},{"key":"512_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cpr.2016.10.002","volume":"51","author":"Z Walsh","year":"2017","unstructured":"Walsh Z, Gonzalez R, Crosby KS, Thiessen M, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15\u201329.","journal-title":"Clin Psychol Rev"},{"issue":"5","key":"512_CR29","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/schbul\/sbw003","volume":"42","author":"A Marconi","year":"2016","unstructured":"Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262\u20139.","journal-title":"Schizophr Bull"},{"issue":"8","key":"512_CR30","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/add.13347","volume":"111","author":"O Rogeberg","year":"2016","unstructured":"Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised: Cannabis and motor vehicle collision risk. Addiction. 2016;111(8):1348\u201359.","journal-title":"Addiction"},{"issue":"6","key":"512_CR31","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1080\/00952990.2019.1627366","volume":"45","author":"DP Tashkin","year":"2019","unstructured":"Tashkin DP, Roth MD. Pulmonary effects of inhaled cannabis smoke. Am J Drug Alcohol Abuse. 2019;45(6):596\u2013609.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"512_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/dar.12323","volume":"35","author":"P Lucas","year":"2016","unstructured":"Lucas P, Walsh Z, Crosby K, Callaway R, Belle-Isle L, Kay R, et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: the impact of contextual factors. Drug Alcohol Rev. 2016;35(3):326\u201333.","journal-title":"Drug Alcohol Rev"},{"key":"512_CR33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugpo.2017.01.011","volume":"42","author":"P Lucas","year":"2017","unstructured":"Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30\u20135.","journal-title":"Int J Drug Policy"},{"key":"512_CR34","doi-asserted-by":"publisher","first-page":"102963","DOI":"10.1016\/j.drugpo.2020.102963","volume":"86","author":"P Lucas","year":"2020","unstructured":"Lucas P, Boyd S, Milloy MJ, Walsh Z. Reductions in alcohol use following medical cannabis initiation: results from a large cross-sectional survey of medical cannabis patients in Canada. Int J Drug Policy. 2020;86:102963.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"512_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12954-019-0278-6","volume":"16","author":"P Lucas","year":"2019","unstructured":"Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids and other pharmaceutical drugs, alcohol, tobacco, and illicit substances: results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):9.","journal-title":"Harm Reduct J"},{"issue":"5","key":"512_CR36","doi-asserted-by":"publisher","first-page":"e0233463-e","DOI":"10.1371\/journal.pone.0233463","volume":"15","author":"S Lake","year":"2020","unstructured":"Lake S, Nosova E, Buxton J, Walsh Z, Socias ME, Hayashi K, et al. Characterizing motivations for cannabis use in a cohort of people who use illicit drugs: a latent class analysis. PLoS ONE. 2020;15(5):e0233463-e.","journal-title":"PLoS ONE"},{"issue":"10","key":"512_CR37","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2105\/AJPH.2020.305825","volume":"110","author":"H Reddon","year":"2020","unstructured":"Reddon H, DeBeck K, Socias ME, Lake S, Dong H, Karamouzian M, et al. Frequent cannabis use and cessation of injection of opioids, Vancouver, Canada, 2005\u20132018. Am J Public Health. 2020;110(10):1553\u201360.","journal-title":"Am J Public Health"},{"issue":"12","key":"512_CR38","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1111\/add.14398","volume":"113","author":"ME Soc\u00edas","year":"2018","unstructured":"Soc\u00edas ME, Wood E, Lake S, Nolan S, Fairbairn N, Hayashi K, et al. High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Addiction. 2018;113(12):2250\u20138.","journal-title":"Addiction"},{"issue":"6","key":"512_CR39","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/dar.12275","volume":"34","author":"N Lau","year":"2015","unstructured":"Lau N, Sales P, Averill S, Murphy F, Sato S-O, Murphy S. A safer alternative: Cannabis substitution as harm reduction. Drug Alcohol Rev. 2015;34(6):654\u20139.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"512_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7517-6-35","volume":"6","author":"A Reiman","year":"2009","unstructured":"Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J. 2009;6(1):35.","journal-title":"Harm Reduct J"},{"issue":"5","key":"512_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3109\/16066359.2012.733465","volume":"21","author":"P Lucas","year":"2013","unstructured":"Lucas P, Reiman A, Earleywine M, McGowan SK, Oleson M, Coward MP, et al. Cannabis as a substitute for alcohol and other drugs: a dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addict Res Theory. 2013;21(5):435\u201342.","journal-title":"Addict Res Theory"},{"issue":"4","key":"512_CR42","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/acer.13964","volume":"43","author":"J Turna","year":"2019","unstructured":"Turna J, Syan SK, Frey BN, Rush B, Costello MJ, Weiss M, et al. Cannabidiol as a novel candidate alcohol use disorder pharmacotherapy: a systematic review. Alcohol Clin Exp Res. 2019;43(4):550\u201363.","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"512_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/acer.13592","volume":"42","author":"HC Karoly","year":"2018","unstructured":"Karoly HC, Bidwell LC, Mueller RL, Hutchison KE. Investigating the relationships between alcohol consumption, cannabis use, and circulating cytokines: a preliminary analysis. Alcohol Clin Exp Res. 2018;42(3):531\u20139.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"512_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1037\/pha0000272","volume":"27","author":"CN Nona","year":"2019","unstructured":"Nona CN, Hendershot CS, Le Foll B. Effects of cannabidiol on alcohol-related outcomes: a review of preclinical and human research. Exp Clin Psychopharmacol. 2019;27(4):359\u201369.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"3","key":"512_CR45","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/alcalc\/agt182","volume":"49","author":"MS Subbaraman","year":"2014","unstructured":"Subbaraman MS. Can cannabis be considered a substitute medication for alcohol? Alcohol Alcohol. 2014;49(3):292\u20138.","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"512_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/0269881111408463","volume":"26","author":"J Chick","year":"2012","unstructured":"Chick J, Nutt DJ. Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol. 2012;26(2):205\u201312.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"512_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1748-5908-4-50","volume":"4","author":"LJ Damschroder","year":"2009","unstructured":"Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(1):50\u201350.","journal-title":"Implement Sci"},{"issue":"1","key":"512_CR48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13012-016-0437-z","volume":"11","author":"MA Kirk","year":"2016","unstructured":"Kirk MA, Kelley C, Yankey N, Birken SA, Abadie B, Damschroder L. A systematic review of the use of the consolidated framework for implementation research. Implement Sci. 2016;11(1):72.","journal-title":"Implement Sci"},{"key":"512_CR49","unstructured":"Harm Reduction International. What is harm reduction. 2021. Available from https:\/\/www.hri.global\/files\/2021\/05\/05\/What_is_Harm_Reduction_English_HRI.pdf."},{"key":"512_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/tobaccocontrol-2020-055755","author":"EC Leas","year":"2020","unstructured":"Leas EC, Nobles AL, Caputi TL, Dredze M, Zhu S-H, Cohen JE, et al. News coverage of the e-cigarette, or vaping, product use associated lung injury (EVALI) outbreak and internet searches for vaping cessation. Tob Control. 2020. https:\/\/doi.org\/10.1136\/tobaccocontrol-2020-055755.","journal-title":"Tob Control"},{"key":"512_CR51","doi-asserted-by":"publisher","first-page":"102737","DOI":"10.1016\/j.drugpo.2020.102737","volume":"79","author":"J Valleriani","year":"2020","unstructured":"Valleriani J, Haines-Saah R, Capler R, Bluthenthal R, Socias ME, Milloy MJ, et al. The emergence of innovative cannabis distribution projects in the downtown eastside of Vancouver, Canada. Int J Drug Policy. 2020;79:102737.","journal-title":"Int J Drug Policy"},{"key":"512_CR52","unstructured":"BC Centre on Substance Use. Risk mitigation in the context of dual public health emergencies; 2020. https:\/\/www.bccsu.ca\/risk-mitigation-in-the-context-of-dual-public-health-emergencies-v1-5\/."},{"key":"512_CR53","unstructured":"BC Centre on Substance Use and Canadian Institute for Substance Use Research. Operational guidance for the implementation of managed alcohol for vulnerable populations; 2020. https:\/\/www.uvic.ca\/research\/centres\/cisur\/assets\/docs\/provincial-guidance-managed-alcohol.pdf."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00512-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:13:16Z","timestamp":1624435996000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00512-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["512"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00512-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the University of Victoria Human Research Ethics Board (HREB) (Protocol 13-002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}